Pharmacogenomics for Prader-Willi syndrome: caregiver interest and planned utilization.

Autor:	Bar-Peled Y; Department of Clinical & Diagnostic Sciences, University of Alabama at Birmingham, AL 35294, USA., Denton JJ; Department of Clinical & Diagnostic Sciences, University of Alabama at Birmingham, AL 35294, USA., Richards JL; Department of Preventive Medicine, University of Alabama at Birmingham, AL 35294, USA.; Department of Genetics & Pediatrics, University of Alabama at Birmingham Heersink School of Medicine, AL 35294, USA., Brown D; Department of Genetics & Pediatrics, University of Alabama at Birmingham Heersink School of Medicine, AL 35294, USA., Worthey E; Department of Genetics & Pediatrics, University of Alabama at Birmingham Heersink School of Medicine, AL 35294, USA., Strong TV; Department of Genetics, University of Alabama at Birmingham Heersink School of Medicine, AL 35294, USA.; Foundation for Prader-Willi Research, Covina, CA 91723, USA.
Jazyk:	angličtina
Zdroj:	Pharmacogenomics [Pharmacogenomics] 2024 Mar; Vol. 25 (4), pp. 207-216. Date of Electronic Publication: 2024 Mar 20.
DOI:	10.2217/pgs-2023-0189
Abstrakt:	Aim: The study aim was to determine caregiver interest and planned utilization of pharmacogenomic (PGx) results for their child with Prader-Willi syndrome. Methods: Caregivers consented to PGx testing for their child and completed a survey before receiving results. Results: Of all caregivers (n = 48), 93.8% were highly interested in their child's upcoming PGx results. Most (97.9%) planned to share results with their child's medical providers. However, only 47.9% of caregivers were confident providers would utilize the PGx results. Conclusion: Caregivers are interested in utilizing PGx but are uncertain providers will use these results in their child's care. More information about provider comfort with PGx utilization is needed to understand how PGx education would benefit providers and ultimately patients with PGx results.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu